Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedDec 14, 2016PAPA/PHEN/PROSTLack of Assurance of Sterility: product produced on a day there was an excursion in environmental monitoring data.Fallon Wellness Pharmacy, L.L.C. · D-0173-2017Class IIITerminatedDec 14, 2016SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE INJECTIONSubpotent Drug: Product has an an out of specification in iron assay analysis found during 18 month stability testing.West-Ward Pharmaceuticals Corp. · D-0172-2017Class IIITerminatedDec 14, 2016Qnasl (beclomethasone dipropionate) Nasal Aerosol 80 McgFailed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing.Teva Pharmaceuticals USA · D-0171-2017Class IIITerminatedDec 14, 2016Qnasl (beclomethasone dipropionate) Nasal Aerosol 40 McgFailed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing.Teva Pharmaceuticals USA · D-0170-2017Class IIITerminatedDec 14, 20165% Lidocaine HCL and 7.5% Dextrose InjectionFailed Stability Specifications: The recalled lots did not meet the specification for color and pH throughout shelf life.Hospira Inc. · D-0169-2017Class IITerminatedDec 7, 2016Phenazopyridine Hydrochloride TabletsCGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.Nationwide Laboratories, LLC · D-0168-2017Class IITerminatedDec 7, 2016Phenazopyridine Hydrochloride TabletsCGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.Nationwide Laboratories, LLC · D-0167-2017Class IITerminatedDec 7, 2016Salsalate TabletsCGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.Nationwide Laboratories, LLC · D-0166-2017Class IITerminatedDec 7, 2016Salsalate TabletsCGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.Nationwide Laboratories, LLC · D-0165-2017Class IITerminatedDec 7, 2016Ondansetron HCI APIMicrobial Contamination of Non-Sterile ProductCadila Pharmaceuticals Limited · D-0164-2017Class IITerminatedDec 7, 2016Metformin Hydrochloride TabletsPresence of Foreign Tablets/Capsules; report of Amlodipine Tablets found in 1000 count bottles of Metformin Hydrochloride Tablets USPAscend Laboratories LLC · D-0163-2017Class IITerminatedDec 7, 2016Phenazopyridine Hydrochloride TabletsCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0162-2017Class IITerminatedDec 7, 2016Phenazopyridine Hydrochloride TabletsCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0161-2017Class IITerminatedDec 7, 2016Indiomin MB URINARY ANTISEPTICCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0160-2017Class IITerminatedDec 7, 2016AZUPHEN MB URINARY ANTISEPTIC CapsulesCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0159-2017Class IITerminatedDec 7, 2016UROPHEN MB URINARY ANTISEPTIC TabletsCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0158-2017Class IITerminatedDec 7, 2016URAMIT MB URINARY ANTISEPTIC CapsulesCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0157-2017Class IITerminatedDec 7, 2016UROLET MB URINARY ANTISEPTICCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0156-2017Class IITerminatedDec 7, 2016Hyolev MB URINARY ANTISEPTIC TabletsCGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failuresBurel Pharmaceuticals Inc · D-0155-2017Class IITerminatedDec 7, 2016Travoprost Ophthalmic Solution USPLack of Assurance of Sterility; damage to the internal portion of the dropper tip portion of the containerPar Pharmaceutical, Inc. · D-0154-2017Class IITerminatedNov 30, 2016Phenobarbital TabletsFailed Dissolution Specifications: Phenobarbital Tablets have an out of specification for dissolution at the 12 month stability time pointWest-Ward Pharmaceuticals Corp. · D-1045-2017Class IITerminatedNov 30, 2016Fentanyl Citrate InjectionLack of Assurance of Sterility: Complaints of broken tips on the ampules.Hospira Inc. · D-0153-2017Class IITerminatedNov 30, 2016Desoximetasone Ointment USPFailed Stability Specifications; out-of specification value for homogeneity / phase separation.Akorn Inc · D-0152-2017Class IIITerminatedNov 30, 2016Diltiazem HCl Extended-release CapsulesFailed Impurities/Degradation Specifications: OOS results for known compound.Mylan Pharmaceuticals Inc. · D-0151-2017Class IITerminatedNov 30, 2016LEVOXYL(R)SuperpotentPfizer Inc. · D-0150-2017Class IIITerminatedNov 30, 2016BuPROPion Hydrochloride Extended-Release TabletsFailed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point.Zydus Pharmaceuticals USA Inc · D-0149-2017Class IIITerminatedNov 30, 2016KENALOGFailed Stability Specifications: Low Out of Specification results for alcohol content.Sun Pharmaceutical Industries, Inc. · D-0148-2017Class IIITerminatedNov 30, 2016Amoxicillin for Oral suspensionLabeling: Label Error on Declared Strength: Some bottles miss a color coded panel where the strength of the product is typically displayed.West-Ward Pharmaceuticals Corp. · D-0147-2017Class IITerminatedNov 30, 2016Lactulose SolutionMicrobial Contamination of Non-Sterile Products: bulk solution tested positive for the presence of the bacteria, Burkholderia cepacia.VistaPharm, Inc. · D-0146-2017Class IIITerminatedNov 30, 2016Ceftriaxone for InjectionLabeling: Missing LabelSandoz Inc · D-0145-2017Class IIITerminatedNov 30, 2016AHP NIFEdipine CapsulesPresence of Foreign Tablets/CapsulesAmerisource Health Services · D-0144-2017Class IIITerminatedNov 30, 2016NIFEdipine Capsules USPPresence of Foreign Tablets/CapsulesActavis Elizabeth LLC · D-0143-2017Class IIITerminatedNov 23, 2016Zeasorb AFLabeling Not Elsewhere Classified: front labels have the incorrect NDC or 0145-1506-01 instead of the correct NDC of 0145-1506-05 and some back labels have the incorrect...GSK Consumer Healthcare · D-0142-2017Class IITerminatedNov 23, 2016L-Cysteine Hydrochloride InjectionLack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.Sandoz Inc · D-0141-2017Class IITerminatedNov 23, 2016L-Cysteine Hydrochloride InjectionLack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.Sandoz Inc · D-0140-2017Class IIITerminatedNov 23, 2016FIRST Omeprazole 2mg/mL in FIRST PPI Suspension Compounding KitLabeling: Label error on declared strength. Package Insert -Error in the Description section of the package insert refers to the strength as 3mg per mL; however it...CutisPharma, Inc. · D-0139-2017Class IIITerminatedNov 23, 2016FIRST Omeprazole 2mg/mL in FIRST PPI Suspension Compounding KitLabeling: Label error on declared strength. Package Insert -Error in the Description section of the package insert refers to the strength as 3mg per mL; however it...CutisPharma, Inc. · D-0138-2017Class IIITerminatedNov 23, 2016Bupropion Hydrochloride Extended-Release TabletsFailed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.Amerisource Health Services · D-0137-2017Class IIITerminatedNov 16, 2016Clonazepam TabletsFailed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 16 month timepoint.Mylan Institutional, Inc. (d.b.a. UDL Laboratories) · D-0136-2017Class IIITerminatedNov 16, 2016Clonazepam TabletsFailed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 15 month timepoint.Mylan Institutional, Inc. (d.b.a. UDL Laboratories) · D-0135-2017